Ranibizumab for myopic choroidal neovascularization
- 12 October 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 20 (12) , 1385-1393
Abstract
Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular ...Keywords
Funding Information
- funded
This publication has 71 references indexed in Scilit:
- Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population ApproachInvestigative Ophthalmology & Visual Science, 2013
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabEye, 2011
- Therapeutic monoclonal antibodies in ophthalmologyProgress in Retinal and Eye Research, 2009
- CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIARetina, 2008
- PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITSRetina, 2007
- Choroidal neovascularisation in pathological myopia: an update in managementBritish Journal of Ophthalmology, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopiaOphthalmology, 2003
- THE ROLE OF THE KIDNEY IN THE CATABOLISM OF BENCE JONES PROTEINS AND IMMUNOGLOBULIN FRAGMENTSJournal of Experimental Medicine, 1967